# Gastric cancer cell proliferation is suppressed by frizzled-2 short hairpin RNA

MINORU TOMIZAWA<sup>1</sup>, FUMINOBU SHINOZAKI<sup>2</sup>, YASUFUMI MOTOYOSHI<sup>3</sup>, TAKAO SUGIYAMA<sup>4</sup>, SHIGENORI YAMAMOTO<sup>5</sup> and NAOKI ISHIGE<sup>6</sup>

Departments of <sup>1</sup>Gastroenterology, <sup>2</sup>Radiology, <sup>3</sup>Neurology, <sup>4</sup>Rheumatology, <sup>5</sup>Pediatrics and <sup>6</sup>Neurosurgery, National Hospital Organization, Shimoshizu Hospital, Yotsukaido City, Chiba 284-0003, Japan

Received November 9, 2014; Accepted December 29, 2014

DOI: 10.3892/ijo.2015.2830

Abstract. In order to identify novel targets for the molecular therapy of gastric cancer (GC), we investigated the mRNA and protein expression of frizzled-2 (Fz2), a Wnt signaling pathway receptor. Reverse-transcriptase polymerase chain reaction (PCR) amplification was utilized to determine the expression patterns of Fz genes in normal stomach and in the GC cell lines MKN45 and MKN74. Immunostaining was performed on surgical specimens of GC using an antibody against Fz2. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay was performed on MKN45 cells and MKN74 cells transfected with Fz2 short-hairpin (sh) RNA. Cell motility was analyzed by scratch assay following Fz2 shRNA. Real-time quantitative PCR was performed to analyze the expression levels of cyclin D1 and matrix metallopeptidase 9 (MMP-9). Fz1, 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 cells. Fz2 was expressed in normal stomach and in MKN45, but not in MKN74 cells. Well-differentiated GC tissue was weakly positive for Fz2 in cell membranes. Fz2 was positive in both the cell membrane and cytoplasm of GC tissues of moderately differentiated and poorly differentiated adenocarcinoma. Signet ring cells were positive for cytoplasmic Fz2. Proliferation of MKN45 and MKN74 cells was suppressed by Fz2 shRNA, and a scratch assay demonstrated that Fz2 shRNA suppressed also MKN45 and MKN74 cell motility. Furthermore, Fz2 shRNA application led to downregulated mRNA expression of both cyclin D1 and MMP-9. Fz2, 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 GC cells. Fz2 shRNA suppressed cell proliferation and motility of MKN45 and MKN74 cells, and downregulated cyclin D1 and MMP-9 expression in these GC cell lines.

## Introduction

Gastric cancer (GC) accounts for 8% of total cases and 10% of total deaths from cancer worldwide (1). Although the endoscopic approach has improved cancer diagnosis and treatment, especially of early GC, prognosis is still poor for advanced types (2,3). Consequently, the development of effective molecular therapies for GC is eagerly awaited.

The Wnt pathway is involved in cell proliferation and differentiation (4). Wnt proteins bind to their receptor, frizzled (Fz), and its co-receptors, low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6), to form a complex (5,6). Once Wnt binds to its receptor complex, cytoplasmic  $\beta$ -catenin is accumulated through inhibition of its degradation by the glycogen synthase kinase (GSK)-3 $\beta$  complex (7).  $\beta$ -catenin acts as a co-factor of the T-cell factor (TCF)/lymphoid enhancer factor (LEF) and activates target genes (8). Activity of the Wnt pathway is also controlled by inhibition of secreted proteins such as dickkopf homolog-3 (9). Constitutive activation of the Wnt pathway leads to abnormal cell growth and the development of GC (10,11).

Wnt5a is upregulated in GC possibly due to demethylation of its promoter (12). The Fz3 and 6 receptors transduce the Wnt signal (13). Furthermore, the expression level of  $\beta$ -catenin has been shown to be upregulated in the MKN-45 GC cell line (14). Notably, upregulated  $\beta$ -catenin has been correlated with poor prognosis of patients with GC (14), and methylation of dickkopf homolog 3 has also been associated with poor prognosis of GC (15). Together, these reports clearly indicate that the Wnt pathway is activated in GC. It was, therefore, expected that inhibition of the Wnt pathway might be developed into a new molecular therapy for GC. In comparison, it has been shown that both downregulation of Fz2 and inhibitors of the Wnt pathway successfully suppress the proliferation of hepatocellular carcinoma and pancreatic cancer cells (16-19).

Therefore, we analyzed the effects of Fz2 inhibition using short hairpin RNA (shRNA) on the proliferation and motility of GC cell lines.

### Materials and methods

This study was approved by the institutional ethics committee of the National Hospital Organization Shimoshizu Hospital,

*Correspondence to:* Dr Minoru Tomizawa, Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital, 934-5 Shikawatashi, Yotsukaido City, Chiba 284-0003, Japan E-mail: nihminor-cib@umin.ac.jp

*Key words:* frizzled genes, real-time quantitative PCR, MTS assay, scratch assay, cyclin D1, matrix metallopeptidase

Yotsukaido City, Japan. Written informed consent was obtained by the commercial source (BioChain, Hayward, CA, USA).

*Cell culture*. The GC cell lines MKN45 and MKN74 were purchased from RIKEN Cell Bank (Tsukuba, Japan). Cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Grand Island, NY, USA). Cell lines were cultured with 5% carbon dioxide at 37°C in a humidified chamber.

*shRNA transfection*. Cells were plated in 6-well plates (Asahi Techno Glass, Tokyo, Japan) and cultured until they reached 80% confluence, then transfected and cultured for an additional 48 h. Fz2 shRNA (OriGene, Rockville, MD, USA) was transfected into cells by using Lipofectamine LTX (Life Technologies), according to the manufacturer's instructions. Briefly, shRNA was incubated with PLUS reagent for 5 min, after which LTX reagent was added. A 15-min incubation at room temperature ensued, and the complex was subsequently applied to the cell culture medium. An shRNA negative control was also purchased from OriGene.

RNA isolation, reverse transcription (RT-), and real-time quantitative polymerase chain reaction (PCR) amplification. Total RNA was isolated from native or transfected cell lines using Isogen (Nippon Gene, Tokyo, Japan), and 5  $\mu$ g used to generate cDNA with SuperScript III and oligo(dT) primers, as per the manufacturer's instructions (Life Technologies). Human whole stomach RNA was purchased from Clontech (Mountain View, CA, USA). PCR primers, annealing temperatures, reaction cycle numbers, and amplicon lengths are shown in Table I. PCR was performed using Taq DNA polymerase (Life Technologies), and products were subjected to analysis by gel electrophoresis in 2% agarose in 1X TAE (40 mM Tris-acetate/1 mM EDTA). Real-time quantitative PCR was performed using the Fast SYBR Green Master Mix (Life Technologies) and analyzed with the MiniOpticon Detection system (Bio-Rad, Hercules, CA, USA). Primer pairs for real-time quantitative PCR and the resultant product sizes were demonstrated in Table I. Real-time quantitative PCR was performed for 40 cycles with 5 sec denaturation at 95°C and 5 sec annealing/extension at 60°C. GAPDH and RPL19 were used as internal controls of RT-PCR and real-time quantitative PCR, respectively.

*Immunostaining*. Serial sections were cut from surgical samples, formalin-fixed, and embedded in paraffin (BioChain). The samples: well-differentiated adenocarcinoma (56-week-old female), moderately-differentiated adenocarcinoma (61-year-old female), poorly-differentiated adenocarcinoma (74-year-old male), and signet ring cells (62-year-old male) (BioChain) were deparaffinized, autoclaved, and incubated first with hydrogen peroxide, and then with 2% normal goat serum in phosphate-buffered saline (PBS) (washing buffer) for 30 min. After overnight incubation with a rabbit polyclonal anti-Fz2 antibody (1:5,000) (Sigma-Aldrich), specimens were rinsed with PBS and subsequently incubated with horse-radish peroxidase-labeled anti-rabbit antibody (1:500) for 2 h

(GE Healthcare, Pittsburgh PA, USA). Next, diaminobenzidine (Dako, Glostrup, Denmark) was applied to the tissue sections as a chromogen, and the nuclei were stained with hematoxylin (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 15 sec. Specimens were observed and photographed under an AX80 microscope (Olympus, Tokyo, Japan).

*Cell proliferation analysis.* Cells were trypsinized, harvested, spread onto 96-well flat-bottom plates (Asahi Techno Glass) at a density of 1,000 cells per well, and incubated for 24 h in DMEM supplemented with 10% FBS. After culturing, cells were transfected with Fz2 shRNA for 72 h. Cell cultures were subjected to 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assays according to the manufacturer's instructions (Promega Corp., Madison, WI, USA). MTS is bio-reduced by cells into a colored formazan product that reduces absorbance at 490 nm. Absorbance was analyzed at a wavelength of 490 nm with an iMark Microplate Absorbance Reader (Bio-Rad).

Scratch assay. Cells were plated on 4-well chamber slides (Becton-Dickinson, Franklin Lakes, NJ, USA). When cells reached confluence, they were scratched with 200  $\mu$ l pipettes, incubated for 48 h and stained with hematoxylin and eosin. The stained slides were observed under an AX80 microscope (Olympus). The distance of the scratched line from the growing edge of the cells was measured at five different time points.

*Statistical analysis.* Cell proliferation and real-time quantitative PCR data were analyzed by a one-factor analysis of variance. Statistical analysis was performed using JMP5.0J software (SAS Institute, Cary, NC, USA). A P-value of <0.05 was set as statistically significant.

## Results

To analyze the expression patterns of Fz genes in normal stomach, and in MKN45 and MKN74 cells, RT-PCR was performed and the products subjected to electrophoresis (Fig. 1A). Fz1, 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 cell lines. Fz2 was expressed in normal stomach and in MKN45, but not in MKN74 cells. This result suggested that the expression of Fz2 varied between the cell lines. To determine the expression levels of Fz2 in normal stomach, and in MKN45 and MKN74 cell lines, real-time quantitative PCR was performed (Fig. 1B). The relative expression levels of Fz2 in MKN45 and MKN74 lines were  $1.94\pm0.85$  and  $0.48\pm0.11$  (mean  $\pm$  standard deviation), respectively, as compared with that in normal stomach. It was therefore confirmed that expression of Fz2 was dependent on the cell line analyzed.

To reveal the expression of Fz2 in GC tissues, surgical specimens were immunostained with an antibody for the Fz2 protein (Fig. 2). Well-differentiated GC was weakly positive for Fz2 staining in the cell membranes (Fig. 2A). Fz2 staining was positive in both the cell membranes and the cytoplasm of GC tissues of moderately-differentiated and poorly-differentiated adenocarcinoma (Fig. 2B and C). Signet ring cells showed positive cytoplasmic staining for Fz2 (Fig. 2D). These results suggested that Fz2 was present in GC tissues, and that

OMC210         5-AATGAAGTTCCCCAGGAC3         RFPCR, JhF1, forward         206         59         30         NM_001           0MC221         5-CAGGTGAAATATGTGGAC3         RFPCR, JhF21, forward         217         59         30         NM_017           0MC221         5-CAGGTGAAATATGTGGAC7GA         RFPCR, JhF21, forward         217         59         30         NM_017           0MC221         5-GAGTGGAATGCA3         RFPCR, JhF2, forward         215         53         30         NM_017           0MC235         5-GAGTGCTGAAGC33         RFPCR, JhF2, forward         215         30         NM_017           0MC738         5-GGATGCTGAAGC33         RFPCR, JhF2, forward         102         52         30         NM_003           0MC738         5-GGATGCTGAAGC33         RFPCR, JhF5, forward         115         53         30         NM_003           0MC738         5-GGATGCTAAGCG33         RFPCR, JhF5, forward         231         57         30         NM_003           0MC730         5-GAGTGCTAAGCG33         RFPCR, JhF5, forward         231         57         30         NM_003           0MC731         5-GAGTGCTAAGCG33         RFPCR, JhF5, forward         231         57         30         NM_003           0MC231         5	Primer name	Sequence	Description	Product size (bp)	Annealing temperature (°C)	Cycle	GenBank
OMC201         5-CANGETGCATTCEAGE3         RFPCR, MF2, forward         247         59         30         NM_012           OMC223         5-GTAGGACCCTTCTAGC3         RFPCR, MF2, forward         247         59         30         NM_012           OMC235         5-GTAGCAGCCCGAAAAAATTG3         RFPCR, MF2, forward         255         53         30         NM_012           OMC235         5-GTGCAGTGCATTTGGC3         RFPCR, MF2, inverse         102         52         30         NM_012           OMC235         5-GGTGCAGTGGCATTTGG3         RFPCR, MF2, inverse         102         52         30         NM_012           OMC235         5-GGTGGTAGGGATTTGG3         RFPCR, MF2, inverse         115         52         30         NM_003           OMC239         5-GGTGTAGTCATCTCCG3         RFPCR, MF2, inverse         231         30         NM_003           OMC230         5-GGCGTTAGGATTTGG3         RFPCR, MF2, inverse         237         30         NM_003           OMC230         5-GGCGTTAGCATCTCCG3         RFPCR, MF7, inverse         237         30         NM_003           OMC230         5-GGCGTTAGCATCGTC3         RFPCR, MF7, inverse         237         30         NM_003           OMC231         5-GGCGTTAGCATCGTC3         RFPCR, MF7, inverse<	OMC219 OMC210	5'-AATGACAAGTTCGCCGAGGAC-3' 5'-GCCAGGTGAAAATACTGTGAGTTFGG-3'	RT-PCR, hFz1, forward RT-PCR_hFz1_reverse	206	59	30	NM_003505
<ul> <li>MCZZZ 3-UNACOLCOLOMANANALOS</li> <li>MUTZZ 5-SUGTUTGATTOCOLOR</li> <li>MUTZZ 5-SUGTUTGATTOCUCOLORAMANALOS</li> <li>MUTZZ 5-SUGTUTGATTOCUCOLORAMANALOS</li> <li>MUTZZ 5-SUGTUTGATTACTOGA</li> <li>S-GGTUTGATTACTOGA</li> <li>S-GGTUTGATTACTOGA</li> <li>S-GGTCALCAGGAGAATTATACOS</li> <li>RTPCR, HFZ, INVER</li> <li>MUTZZ 5-GGAATGACATTACTOGA</li> <li>MULDIZ</li> <li>S-GGAATGACAACGATTAGA</li> <li>MULDIZ</li> <li>S-GGAATGACAACGAATGATTAG</li> <li>RTPCR, HFZ, INVER</li> <li>MULDIZ</li> <li>S-GGAATGACAACGAATGATTAG</li> <li>RTPCR, HFZ, INVER</li> <li>MULDIZ</li> <li>S-AGGAACAACGAACGAATGAATGA</li> <li>RTPCR, HFZ, INVER</li> <li>MULDIZ</li> <li>S-AGGAACAACGAATGAATGAATGAA</li> <li>RTPCR, HFZ, INVER</li> <li>MULDIZ</li> <li>S-AGGAATGAACGAATGAATGAA</li> <li>RTPCR, HFZ, INVER</li> <li>MULDIZ</li> <li>S-AGGAATGAATGAATGAATGAA</li> <li>RTPCR, HFZ, INVER</li> <li>MULDIZ</li> <li>S-GGCATTAGAAGGAAGGAAGGA</li> <li>RTPCR, HFZ, INVER</li> <li>MULDIZ</li> <li>S-GCCCATTAGAAGGAAGGAAGGAAGGA</li> <li>MULDIZ</li> <li>S-GCCCATTAGAAGGAAGGAAGGA</li> <li>MULDIZ</li> <li>S-GCCCATTAGAAGGAAGGAAGGAAGGAAGGA</li> <li>MULDIZ</li> <li>S-GCCCTTAGAAGAAGGAAGGAAGGAAGGA</li> <li>MULDIZ</li> <li>S-GCCCTTAGAAGAAGGAAGGAAGGAAGGA</li> <li>MULDIZ</li> <li>S-GCCCTTAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAG</li></ul>	OMC221	5'-CAAGGTGCCATCCTATCTCAGC-3'	RT-PCR, hFz2, forward	247	59	30	NM_001466
0MC26         5*TCCTTGTCACTGTGAAGCC3         RFPCR, hFz, ieverse         3           0MC27         5*GCTCACACAG0AACTTTACG3         RFPCR, hFz, ieverse         32         30         MJ012           0MC73         5*GCTCACACAG0AACTTTACG3         RFPCR, hFz, ieverse         115         52         30         MJ012           0MC73         5*GGACTGCTTAGCGGATTTG3         RFPCR, hFz, ieverse         115         52         30         MJ013           0MC730         5*GGACTGCTTAGCGGA         RFPCR, hFz, ieverse         251         57         30         NM_003           0MC230         5*GGCATTAGCACTCCTCG3         RFPCR, hFz, ieverse         287         58         30         NM_003           0MC230         5*GGCATTAGCACTCCTCG3         RFPCR, hFz, ieverse         287         58         30         NM_003           0MC231         5*AGCATTAGCACTCTCGG3         RFPCR, hFz, ieverse         287         58         30         NM_003           0MC231         5*AGCATTAGCACTCTCGG3         RFPCR, hFz, ieverse         37         30         30         NM_003           0MC233         5*AGCATTAGCACTCTCGG3         RFPCR, hFz, ieverse         37         30         30         M001           0MC233         5*AGCCCTTATGCATGC3         RFPCR, hFz, ieverse	OMC235	5-GIAGCAGGACTGTCATTTGCTCGC-3	RI-FUR, IIFZ2, reverse RT-PCR, hFz3, forward	255	53	30	NM_017412
000727         5-AGGTCTGCTGAACTTTACTG-3         RFPCR, hF24, forward         102         52         30         NM_012           0007731         5-GGTCTCACAGGAGGATTTACG-3         RFPCR, hF24, forward         115         52         30         NM_012           0007731         5-GGTGCTACAGGAGGATTTACG-3         RFPCR, hF26, forward         115         52         30         NM_0012           0007731         5-AGGACGATGCATGGGAGTTTG-3         RFPCR, hF26, forward         251         57         30         NM_0033           0007230         5-AGGACGACGCAGGAGG-3         RFPCR, hF26, forward         251         57         30         NM_0033           0007231         5-AGACTTAGCAGTGCAGGAGG-3         RFPCR, hF27, forward         287         58         30         NM_0033           0007234         5-AGACTGACCAGGAGGAGG-3         RFPCR, hF27, forward         137         59         30         NM_0031           0007234         5-AGACTGACCAGGAGGAGG-3         RFPCR, hF26, forward         137         59         30         NM_0031           0007234         5-AGCCGCTGA-3         RFPCR, hF26, forward         122         59         30         NM_0031           000724         5-AGCCGTGA-3         RFPCR, hF26, forward         122         59         30 <td< td=""><td>OMC236</td><td>5'-TCCTTGTGTCACTGTGGAAGCC-3'</td><td>RT-PCR, hFz3, reverse</td><td></td><td></td><td></td><td></td></td<>	OMC236	5'-TCCTTGTGTCACTGTGGAAGCC-3'	RT-PCR, hFz3, reverse				
0MC238         5-GCTCACAGGAAGAGATTTATGG-3         RT-PCR, hE2, neverse         3 <t< td=""><td>OMC727</td><td>5'-AGGTCTGCTGAACTTTACTG-3'</td><td>RT-PCR, hFz4, forward</td><td>102</td><td>52</td><td>30</td><td>NM_012193</td></t<>	OMC727	5'-AGGTCTGCTGAACTTTACTG-3'	RT-PCR, hFz4, forward	102	52	30	NM_012193
0MC731         5-GGAGTGCTTAGCGGTTTTG-3         RTPCR, hFz6, forward         115         52         30         AB04370           0MC732         5-AGGACACGGGGTCG-3         RTPCR, hFz6, forward         115         52         30         AB04370           0MC230         5-AGGACACGGGGTCG-3         RTPCR, hFz6, forward         251         57         30         NM_003           0MC231         5-AGGACGCACGCTCGG-3         RTPCR, hFz6, forward         287         58         30         NM_003           0MC231         5-AGGACGACGAGCAGG-3'         RTPCR, hFz6, forward         287         58         30         NM_0103           0MC231         5-ACGCTGCAGGCAGC3'         RTPCR, hFz6, forward         157         59         30         NM_0103           0MC233         5-ACGCTGCAGGCAGC3'         RTPCR, hFz6, forward         157         59         30         NM_0103           0MC234         5-ACGCTGCAGCGACG3'         RTPCR, hFz6, forward         157         59         30         NM_0103           0MC234         5-ACGCTGCAGCGACG3'         RTPCR, hFz6, forward         167         59         30         NM_002           0MC724         5-GGATGGCACTAAGGC3'         RTPCR, hFz0, inverse         122         30         NM_002           0MC724 </td <td>OMC728</td> <td>5'-GCTCACACAGGAAGAGATTTATGG-3'</td> <td>RT-PCR, hFz4, reverse</td> <td></td> <td></td> <td></td> <td></td>	OMC728	5'-GCTCACACAGGAAGAGATTTATGG-3'	RT-PCR, hFz4, reverse				
OMC732         5-AAGACAAGGATGGTGC 3         RTPCR, hFZ, reverse         57         30         NM_003           0MC230         5-AGCACACGACTCCACTCCTCG         RTPCR, hFZ, reverse         57         30         NM_003           0MC231         5-AGCACTCCACTCCCTG         RTPCR, hFZ, reverse         287         58         30         NM_003           0MC231         5-AGCACTCCACTCCTG         RTPCR, hFZ, reverse         287         58         30         NM_003           0MC231         5-AGACTAGTCCACTCTCG         RTPCR, hFZ, reverse         287         58         30         NM_003           0MC232         5-AGACTAGTCGATGCC3         RTPCR, hFZ, reverse         287         59         30         NM_003           0MC233         5-ACCGTTATCATCTTCGG         RTPCR, hFZ, reverse         167         59         30         NM_003           0MC234         5-ACCGTTGAGGATGGTTGGG         RTPCR, hFZ, reverse         167         59         30         NM_003           0MC724         5-GGGTAGGAGATGGTTGGG         RTPCR, hFZ, reverse         167         59         30         NM_003           0MC724         5-GGGTAGGTGGTGGGAG         RTPCR, hFZ, reverse         167         59         30         NM_003           0MC725         5-GTGGTGGTGGTGGGAG	OMC731	5'-GGAGTGCTTAGCGGTTTTTG-3'	RT-PCR, hFz5, forward	115	52	30	AB043702
0MC229         5'-AGCAGCATCCATCTC-3         RT-PCR, hFZ6, forward         251         57         30         NM_003           0MC231         5'-GTGAATCCATCTCCGGACTCGG3         RT-PCR, hFZ6, forward         251         57         30         NM_003           0MC231         5'-GTGAATCAACCACTCTCG3         RT-PCR, hFZ6, forward         287         58         30         NM_003           0MC231         5'-ATCCAAGCAGCAGCAGGAG         RT-PCR, hFZ6, forward         137         59         30         NM_0031           0MC231         5'-ATCCAAGCAGCAGCAGCAAGG3         RT-PCR, hFZ6, forward         137         59         30         NM_0031           0MC234         5'-AGCTGTGACTAGCAGCAGCAAGC3         RT-PCR, hFZ6, forward         137         59         30         NM_0031           0MC234         5'-AGGTGAGCAAGCCAATCCAATAC3         RT-PCR, hFZ6, forward         167         59         30         NM_007           0MC724         5'-GGTGAGTGAGCAATCCAATAC3         RT-PCR, hFZ0, forward         167         59         30         NM_007           0MC724         5'-GGTGAGTAGCCAATCCAATAC3         RT-PCR, hFZ0, forward         122         30         NM_007           0MC724         5'-GGTGAGTAGCCAATCCAATAC3         RT-PCR, hFZ0, forward         246         63         30	OMC732	5'-AAGACACAACGATGGTGC-3'	RT-PCR, hFz5, reverse				
0MC230       5-CTGAATGACACCACTCCTG-3'       RT-PCR, hF26, reverse       287       58       30       NM_0033         0MC231       5-AGACTTATCATCATCATCTTCTG-3'       RT-PCR, hF27, invarte       287       58       30       NM_0033         0MC233       5-AGACTTATCATCATCATCATCATCTG-3'       RT-PCR, hF26, invarte       287       59       30       NM_0313         0MC234       5-AGACGTGGAAGC3'       RT-PCR, hF28, inverse       137       59       30       NM_0313         0MC234       5-AGATGGAGGGAAC3'       RT-PCR, hF28, inverse       167       59       30       NM_031         0MC234       5-AGATGACGATGGCATGGAAG3'       RT-PCR, hF28, inverse       167       59       30       NM_031         0MC234       5-AGATGACGATGGCATTGGG3       RT-PCR, hF20, inverse       122       53       30       NM_007         0MC725       5-GGATGACGCATTGGGAA3'       RT-PCR, hF20, inverse       122       53       30       NM_007         0MC724       5-GGGTAGCGCATGTAATAC-3'       RT-PCR, hF20, inverse       246       63       30       NM_007         0MC723       5-GGGTAGCGCATGTAAGA-3'       RT-PCR, hF20, inverse       246       63       30       NM_001         0MC21       5-ACCTGGCGCGTGGAAG3'       RT-PCR, hF20, in	OMC229	5'-AGCAGCATCCATCTCCAGACTCTC-3'	RT-PCR, hFz6, forward	251	57	30	NM_003506
0MC231         5-AGACTTAGCACAGGAGG-3         RT-PCR, hF27, forward         287         58         30         NM_0031           0MC232         5-GGCGTTATCATCATCTCG-3         RT-PCR, hF27, forward         287         58         30         NM_0031           0MC233         5-AGCGGTTATCATCATCTGG-3         RT-PCR, hF27, forward         137         59         30         NM_0311           0MC234         5-AGCGGTGAGGAGGAAGC-3         RT-PCR, hF29, forward         167         59         30         NM_001           0MC725         5-GGTGAGGGTGGGAAC-3         RT-PCR, hF29, forward         167         59         30         NM_007           0MC726         5-GGTGAGGGTCTTGGAG-3         RT-PCR, hF20, forward         122         59         30         NM_007           0MC725         5-GGGTGAGGCTCTTGGTGA-3         RT-PCR, hF20, forward         122         59         30         NM_007           0MC721         5-GGGTAAGCTCTTGTGTA-3         RT-PCR, hGAPDH, forward         246         63         30         NM_007           0MC21         5-ACCTGACTGTGTGTA-3         RT-PCR, hGAPDH, forward         246         63         30         NM_007           0MC21         5-ACCTGACGTCTGGTGA-3         RT-PCR, hGAPDH, forward         246         63         40         N	OMC230	5'-CTGAATGACAACCACCTCCCTG-3'	RT-PCR, hFz6, reverse				
OMC232     5'-GGCGTTATCATCTTCCTG-3'     RT-PCR, hF27, reverse     39     NM_031       OMC233     5'-ATCCAAGGGGTGGGAAC-3'     RT-PCR, hF28, reverse     137     59     30     NM_031       OMC234     5'-ATCCAAGGGGTGGGGAC-3'     RT-PCR, hF28, reverse     167     59     30     BC_0263       OMC234     5'-ATCCAAGGGGTGGGCAC-3'     RT-PCR, hF29, reverse     167     59     30     BC_0263       OMC725     5'-GGGTGGCGCAAGCCAAGCCAAGCCAAAGCCAA     RT-PCR, hF20, forward     122     52     30     NM_007       OMC724     5'-GGGTAGCAAGCCAATGC3'     RT-PCR, hF20, forward     122     52     30     NM_002       OMC724     5'-GGGTAGCATCGAAAGCCATCAAAGC3'     RT-PCR, hF20, forward     246     63     30     NM_002       OMC724     5'-GGGTAGCATCGAAAGCCATCCAATAC3'     RT-PCR, hF20, forward     246     63     30     NM_002       OMC724     5'-ACCTGAAGCCATCGAAAGCAAGCAAGCAAGCAAGCAAGCA	OMC231	5'-AGACTTAGCCACAGCAGCAGGAAGG-3'	RT-PCR, hFz7, forward	287	58	30	NM_003507
OMC2335'-ATCCAAAGCAGTGTC3RT-PCR, hF28, forward1375930NM_0318OMC2345'-ACACTGTGAAGGGTGGGAAC3'RT-PCR, hF28, reverse1675930NM_0318OMC2255'-GGCTCTACTACTTCGGC-3'RT-PCR, hF29, forward1675930NM_007OMC7265'-GGATGGCTCTTGTGAAC-3'RT-PCR, hF29, forward1675930NM_007OMC7255'-GGATGGCTCTTGTGAAC-3'RT-PCR, hF20, forward1225230NM_007OMC7245'-GGGTAGCAACGCTCTTGTGAAC-3'RT-PCR, hF210, forward1225230NM_007OMC7235'-GGGTAGCAACGCTCTTGGTAA-3'RT-PCR, hF210, reverse2466330NM_007OMC7245'-GCCAGCTCTGCGTCTAGAA-3'RT-PCR, hF210, reverse2466330NM_007OMC7255'-GCCAGCTGCGTCTAGAA-3'RT-PCR, hF22, forward1836.2.540NM_007OMC2075'-TCCTCCAGCTCTAGTG-3'GPCR, hF22, forward1836.2.540NM_007OMC3075'-TCGTCGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	OMC232	5'-CGCCGTTATCATCATCTTCCTG-3'	RT-PCR, hFz7, reverse				
0MC234       5-AACACTGTGAAGGGGTGGGAAC-3'       RT-PCR, hF28, reverse       30       BC_0263         0MC725       5-ACTGCTCTACTTCGGC-3'       RT-PCR, hF29, forward       167       59       30       BC_0263         0MC726       5-GGATGACGTCTTGGGT-3'       RT-PCR, hF29, forward       167       59       30       BC_0263         0MC723       5-GGATGACGTCTTGGTAAC-3'       RT-PCR, hF20, reverse       52       30       NM_007         0MC724       5-GGGTAGCCACTCTGGTGAAC-3'       RT-PCR, hF210, reverse       122       52       30       NM_007         0MC71       5-GGGTAGCACTCTGGTGAAC-3'       RT-PCR, hF210, reverse       246       63       30       NM_007         0MC21       5-ACCTGACCTGTGTGAAC-3'       RT-PCR, hF210, reverse       246       63       30       NM_007         0MC21       5-ACCTGACGTGTGTGAA-3'       RT-PCR, hF210, reverse       246       63       30       NM_001         0MC21       5-ACCTGACGTGTGTGA-3'       RT-PCR, hGAPH, reverse       183       62.5       40       NM_001         0MC230       5-TCCACGGGGGGGGGGGGGGAAC-3'       QCR, hF22, reverse       183       62.5       40       NM_001         0MC308       5-TCGGTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	OMC233	5'-ATCCAAAGCAGATGCCATTGTC-3'	RT-PCR, hFz8, forward	137	59	30	NM_031866
OMC7255'-ACTGCTCTACTACTACTGGC-3'RT-PCR, hF29, forward1675930BC_0263OMC7265'-GGAGGGATGGTCTTGGG-3'RT-PCR, hF29, reverse5'-GGATGGCTCTTGTGTAAC-3'RT-PCR, hF20, reverse30NM_007OMC7245'-GGGTAGCCACTCAAATAC-3'RT-PCR, hF210, reverse5'-GGGTAGCCACTCAAATAC-3'RT-PCR, hF210, reverse30NM_007OMC7245'-GGGTAGCCACTCAAATAC-3'RT-PCR, hF210, reverse6-330NM_002OMC215'-ACCTGGCCGTCTGGAA-3'RT-PCR, hGAPDH, reverse6-330NM_002OMC3075'-TCCACCCCTGTTGCTGTA-3'RT-PCR, hGAPDH, reverse1836-2.540NM_001OMC3075'-TCCACCCCTGTTGCTGTA-3'RT-PCR, hF22, forward1836-2.540NM_001OMC3075'-TCCACCCTGTTGCTGTA-3'RT-PCR, hF22, forward1836-2.540NM_001OMC3085'-TGGTGGAGGAGGAGGAGG-3'qPCR, hF22, reverse1806040NM_001OMC3085'-GGGGGGGGGGGGGGAGGAGC3'qPCR, hCyclin D1, reverse896040NM_004'OMC3085'-GGGGGAGGAGGAGCAG-3'qPCR, hMMP9, forward896040NM_004'OMC3055'-GGGGGAGGAGGAGTGGA-3'qPCR, hMMP9, reverse896040NM_004'OMC7495'-GCAGGGAGGAGTAGC-3'qPCR, hRPL19, reverse896040NM_004'OMC7405'-GCAAGTCCCAAACCT-3'qPCR, hRPL19, reverse896040NM_004'OMC7405'-GCAAGGCGAGGAGTAGCT-3'qPCR, hRPL19,	OMC234	5'-AACACTGTGAAGGGGGGGGGGAAC-3'	RT-PCR, hFz8, reverse				
OMC7265-GGATGACGATGGATGG-3'RT-PCR, hFz9, reverse0MC7235'-GTGAAGGATGGATCAGC-3'RT-PCR, hFz10, forward1225230NM_007'0MC7245'-GGGTAGCCACTCAAATAC-3'RT-PCR, hFz10, reverse5'-GGGTAGCAAGCCAACTCAAATAC-3'RT-PCR, hGAPDH, forward1225230NM_002'0MC215'-ACCTGACCTGCGGTCTAGAA-3'RT-PCR, hGAPDH, forward2466330NM_002'0MC225'-TCCACCACCTGTTGGTGTA-3'RT-PCR, hGAPDH, reverse18362.540NM_001'0MC3075'-TCCTCAAGGTGGCAGGAGGAGGAGGAGGAGGAGGGGGGGG	OMC725	5'-ACTGCTCTACTACTTCGGC-3'	RT-PCR, hFz9, forward	167	59	30	$BC_{026333}$
0MC7235'-GTGAAGTAGCTCTTGTGTAAC-3'RT-PCR, hFz10, forward1225230NM_00710MC7245'-GGGTAGCCAACTCAAATAC-3'RT-PCR, hFz10, reverse5230NM_00200MC215'-ACCTGACCTGCCGTCTAGAA-3'RT-PCR, hGAPDH, forward2466330NM_00200MC225'-TCCACCCCTGTTGCTGTA-3'RT-PCR, hGAPDH, reverse6330NM_00200MC225'-TCCACCACCTGTTGCTGTA-3'RT-PCR, hGAPDH, reverse6330NM_00100MC3075'-TCCACACTCAGTGTGGTGGA-3'RT-PCR, hFz2, forward18362.540NM_00100MC3085'-TGGTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	OMC726	5'-GGATGACGATGGTCTTGAG-3'	RT-PCR, hFz9, reverse				
0MC7245-GGGTAGCAAGCCAACTCAAATAC-3'RT-PCR, hFz10, reverse0MC215-ACCTGACCTGCGTCTAGA-3'RT-PCR, hGAPDH, forward2466330NM_0020MC225-ACCTGACCTGCGTCTAGA-3'RT-PCR, hGAPDH, reverse6330NM_0010MC3075-TCCACCACCTGTTGCTGTA-3'RT-PCR, hFz2, forward18362.540NM_0010MC3085-TCCTCAAGGTGCATCCTATCTC-3'qPCR, hFz2, forward18362.540NM_0010MC3085-TGGTGACGGTGGAGGAGGTGGAAG-3'qPCR, hFz2, forward18362.540NM_0530MC3055-AGGGGGAGGAGGAGGAGGTGG-3'qPCR, hCyclin D1, forward1806040NM_0530MC3055-AGGGGGAGGTAGGAAGAACG-3'qPCR, hMP9, forward896040NM_0640MC7495-CCTGGGCAGATCCAACCT-3'qPCR, hMP9, reverse896040NM_0040MC7505-GCAAGTCTCGAGTAGTTTGGAT-3'qPCR, hMP9, reverse896040NM_0040MC7515-CCATGAGGAGGTAGCTAC-3'qPCR, hRPL19, reverse896040NM_0040MC3215-CCATGAGAAGGTCG-3'qPCR, hRPL19, reverse5-CCATGAGAAGGTCG-3'6PCR, hRPL19, reverse6040800MC3225-CCATGAGAAGGTCGTTGTT-3'qPCR, hRPL19, reverse60404080	OMC723	5'-GTGAAGTAGCCTCTTGTGTGTAAC-3'	RT-PCR, hFz10, forward	122	52	30	NM_007197
0MC215'-ACCTGACCTGCGTCTAGA-3'RT-PCR, hGAPDH, forward2466330NM_0020MC225'-TCCACCCTGTTGCTGTA-3'RT-PCR, hGAPDH, reverse6330NM_0010MC3075'-TCCACCACCTGTTGCTGTA-3'qPCR, hFz2, forward18362.540NM_0010MC3085'-TGGTGACGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	OMC724	5'-GGGTAGCAAGCCAACTCAAATAC-3'	RT-PCR, hFz10, reverse				
OMC225'-TCCACCACCTGTTGCTGT-3'RT-PCR, hGAPDH, reverseOMC3075'-TCCTCAAGGTGCATCCTATCTC-3'qPCR, hFz2, forward18362.540NM_001/OMC3085'-TGGTGAAGGTGGAAGG-3'qPCR, hFz2, reverse18362.540NM_0033OMC3055'-TGGTGACGTGGAGGAGGAGG-3'qPCR, hFz2, reverse1806040NM_053OMC3555'-AGGGGGAGGAGGAAGTTG-3'qPCR, hCyclin D1, reverse896040NM_053OMC3565'-AGGCGGTAGTAGGAAGTTG-3'qPCR, hMP9, forward896040NM_004'OMC7495'-CCTGGGCAGTAGTTGGAT-3'qPCR, hMP9, reverse896040NM_004'OMC7305'-GCAAGTTCCAAACCT-3'qPCR, hMP9, reverse576040NM_004'OMC7315'-CGTGGGAGGAGGAGGTCC-3'qPCR, hRPL19, forward1576040BC09544OMC3225'-CCTGGGAGTAGTTTGGAT-3'qPCR, hRPL19, reverse576040BC09544	OMC21	5'-ACCTGACCTGCCGTCTAGAA-3'	RT-PCR, hGAPDH, forward	246	63	30	NM_002046
OMC3075'-TCCTCAAGGTGCCATCCTATCTC-3'qPCR, hFz2, forward18362.540NM_001OMC3085'-TGGTGAGGAGGAGGAGGAG-3'qPCR, hFz2, reverse40NM_053OMC3085'-AGGGGGAGGAGGAGAACAACAG-3'qPCR, hFz2, reverse40NM_053OMC3555'-AGGGGGAGGAGGAACAACAG-3'qPCR, hCyclin D1, forward1806040NM_053OMC3565'-AGGCGGTAGTAGGAAGTTG-3'qPCR, hMMP9, forward896040NM_004!OMC7495'-CCTGGGCAGGAGGAGTTGGAT-3'qPCR, hMMP9, reverse896040NM_004!OMC7505'-GCAAGTCTCCGAGTAGTTTGGAT-3'qPCR, hMMP9, reverse1576040BC09544OMC3215'-CGAATGCCAGAGAGGTCAC-3'qPCR, hRPL19, reverse1576040BC09544OMC3225'-CCATGAGAATCCGCTTGTTT-3'qPCR, hRPL19, reverse1576040BC09544	OMC22	5'-TCCACCACCTGTTGCTGTA-3'	RT-PCR, hGAPDH, reverse				
OMC3085'-TGGTGACAGTGAAGAGG7GqPCR, hFz2, reverseOMC3555'-AGAGGGGAGGAGGAGG-3'qPCR, hCycln D1, forward1806040NM_053OMC3565'-AGGGGGAGGAGGAAGTTG-3'qPCR, hCyclin D1, reverse896040NM_064OMC7495'-CCTGGGCAGGTAGTTTTGGAT-3'qPCR, hMMP9, forward896040NM_004OMC7505'-GCAGGTAGTTTTGGAT-3'qPCR, hMMP9, reverse896040NM_004OMC7505'-GCAGGTAGTAGTTTTGGAT-3'qPCR, hMMP9, reverse1576040BC09544OMC3215'-CGATGCCAGAGGTAGTTTTGGAT-3'qPCR, hRPL19, forward1576040BC09544OMC3225'-CCATGAGAATCCGCTTGTTT-3'qPCR, hRPL19, reverse576040BC09544	OMC307	5'-TCCTCAAGGTGCCATCCTATCTC-3'	qPCR, hFz2, forward	183	62.5	40	NM_001466
OMC3555'-AGAGGGAGGAGAACAACAG-3'qPCR, hCyclin D1, forward1806040NM_053OMC3565'-AGGCGGTAGTAGGAAGTTG-3'qPCR, hCyclin D1, reverse896040NM_004!OMC7495'-CCTGGGCAGATTCCAAACCT-3'qPCR, hMMP9, forward896040NM_004!OMC7505'-GCAGGTAGTAGGTAGTTTGGAT-3'qPCR, hMMP9, reverse896040NM_004!OMC7505'-GCAGGCAGGAGGTAGTTTGGAT-3'qPCR, hMMP9, reverse1576040BC09544OMC3215'-CGATGCCAGAGGTAGTTT-3'qPCR, hRPL19, forward1576040BC09544OMC3225'-CCATGAGAATCCGCTTGTTT-3'qPCR, hRPL19, reverse1576040BC09544	OMC308	5'-TGGTGACAGTGAAGAAGGTGGAAG-3'	qPCR, hFz2, reverse				
OMC3565'-AGGCGGTAGTAGGAGGTTG-3'qPCR, hCyclin D1, reverseOMC7495'-CCTGGGCAGATTCCAACCT-3'qPCR, hMMP9, forward896040NM_004!OMC7505'-CCTGGGCAGTAGTTTTGGAT-3'qPCR, hMMP9, reverse896040NM_004!OMC7515'-GCAAGTCTTCCGAGTAGTTTTGGAT-3'qPCR, hRMP19, forward1576040BC09544OMC3215'-CGATGCCAGAGAAGGTCAC-3'qPCR, hRPL19, forward1576040BC09544OMC3225'-CCATGAGAAGGTCATT-3'qPCR, hRPL19, reverse1576040BC09544	OMC355	5'-AGAGGCGGAGGAGAACAAACAG-3'	qPCR, hCycln D1, forward	180	09	40	NM_053056
OMC7495'-CCTGGGCAGATTCCAACCT-3'qPCR, hMMP9, forward896040NM_004!OMC7505'-GCAAGTCTTCCGAGTAGTTTTGGAT-3'qPCR, hMMP9, reverse5'-GCAAGTCTCCGAGAAGGTCAC-3'qPCR, hRPL19, forward1576040BC09544OMC3215'-CCATGAGAAGGTCAC-3'qPCR, hRPL19, forward1576040BC09544OMC3225'-CCATGAGAATCCGCTTGTTT-3'qPCR, hRPL19, reverse	OMC356	5'-AGGCGGTAGTAGGACAGGAAGTTG-3'	qPCR, hCyclin D1, reverse				
OMC7505'-GCAAGTCTTCCGAGTAGTTTTGGAT-3'qPCR, hMMP9, reverseOMC3215'-CGAATGCCAGAGAAGGTCAC-3'qPCR, hRPL19, forward1576040OMC3225'-CCATGAGAATCCGCTTGTTT-3'qPCR, hRPL19, reverse	OMC749	5'-CCTGGGCAGATTCCAAACCT-3'	qPCR, hMMP9, forward	89	09	40	NM_004994
OMC321 5'-CGAATGCCAGAGAGGTCAC-3' qPCR, hRPL19, forward 157 60 40 BC09544 OMC322 5'-CCATGAGAATCCGCTTGTTT-3' qPCR, hRPL19, reverse	OMC750	5'-GCAAGTCTTCCGAGTAGTTTTTGGAT-3'	qPCR, hMMP9, reverse				
OMC322 5'-CCATGAGAATCCGCTTGTTT-3' aPCR, hRPL19, reverse	OMC321	5'-CGAATGCCAGAGAAGGTCAC-3'	qPCR, hRPL19, forward	157	09	40	BC095445
	OMC322	5'-CCATGAGAATCCGCTTGTTT-3'	qPCR, hRPL19, reverse				

'n 5 È, ì, 5 à 5 2 5 ÷ metallopeptidase 9; RPL19, ribosomal protein L (RPL) 19.

Table I. Primers of polymerase chain reaction.



Figure 1. Expression patterns of frizzled. (A) Expression patterns of frizzled genes were analyzed using reverse-transcriptase polymerase chain reaction amplification. (B) The expression levels of frizzled-2 in normal stomach and gastric cancer cell lines were analyzed using real-time quantitative polymerase chain reaction amplification. Normal, normal stomach; error bar, standard deviation; N=3.



Figure 2. Expression of frizzled-2 in gastric cancer tissues and cell lines. Expression of frizzled-2 was analyzed immunohistochemically in surgical specimens of well-differentiated adenocarcinoma (A), moderately differentiated adenocarcinoma (B), poorly differentiated adenocarcinoma (C) and signet-ring cells (D). Arrows, cancer cells; original magnification, x400; scale bar, 50  $\mu$ m.

its expression levels are dependent on the grade of pathological differentiation.

To address the possibility that proliferation of GC cell lines might be suppressed with downregulation of Fz2, Fz2 shRNA was transfected into the GC MKN45 and MKN74 cell lines (Fig. 3). Proliferation of the MKN45 cell line was suppressed to  $53.2\pm23.4\%$  of that of mock transfected cells (P<0.05) at 100 ng/well MTS (Fig. 3A); similarly, proliferation of MKN74 cells was suppressed to  $59.9\pm38.2\%$  (P<0.05) of that of mock transfected cells at 100 ng/well MTS (Fig. 3B).

To confirm the downregulation of Fz2 by Fz2 shRNA, the expression levels of the Fz2 gene were quantitated. Expression levels of cyclin D1, involved in cell proliferation (20), were also analyzed. Quantitative real-time PCR demonstrated that



Figure 3. Cell proliferation assay. Cell proliferation was analyzed in MKN45 (A) and MKN74 (B) cells by using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay 72 h after transfection of Fz2 shRNA. Mock, mock transfection; neg, negative control; \*P<0.05 (one-factor analysis of variance); error bar, standard deviation; N=3.



Figure 4. Expression levels of cyclin D1. Expression levels of Fz2 (A and C) and cyclin D1 (B and D) were analyzed by quantitative real-time polymerase chain reaction (PCR) in MKN45 (A and B) and MKN74 cells (C and D) transfected with Fz2 shRNA. Mock, mock transfected; neg, transfected with negative control; 0.25  $\mu$ g, transfected with 0.25  $\mu$ g shRNA; 2.5  $\mu$ g, transfected with 2.5  $\mu$ g shRNA; \*P<0.05 (one-factor analysis of variance); error bar, standard deviation; N=3.

the expression levels of Fz2 and cyclin D1 in MKN45 cells were downregulated to  $64.9\pm15.9\%$  (P<0.05) and  $56.7\pm6.6\%$ (P<0.05) of mock-transfected cells, respectively, at  $2.5 \mu g$ /well Fz2 shRNA (Fig. 4A and B). In the MKN74 cell line, the expression levels of Fz2 and cyclin D1 were downregulated to  $3.8\pm0.4\%$  (P<0.05) and  $3.7\pm0.8\%$  (P<0.05) of those in mocktransfected cells, respectively, at  $2.5 \mu g$ /well Fz2 shRNA (Fig. 4C and D).

To address the possibility that shRNA of Fz2 suppressed cell motility, a scratch assay was performed. Following trans-

fection, the cell sheet was scratched and distance of migration was measured over a set time length (Fig. 5A-D). Distance of migration was suppressed from 607±102  $\mu$ m in mock transfected MKN45 cells to 261±47  $\mu$ m (P<0.05) at 2.5  $\mu$ g/well Fz2 shRNA (Fig. 5E). Similarly, the distance of migration was suppressed from 209±43  $\mu$ m in mock transfected MKN74 cells to 52±12  $\mu$ m (P<0.05) at 2.5  $\mu$ g/well Fz2 shRNA (Fig. 5F).

To reveal the mechanism of suppression of cell motility, the expression levels of MMP9, a gene involved in cancer metastasis (21), were quantitated. MMP9 was downregulated to



Figure 5. Scratch assay. MKN45 (A and C) or MKN74 cells (B and D) were cultured on chamber slides. The cells were scratched with the tip of a 200- $\mu$ l pipette tip (solid line) and treated with (C and D) or without (A and B) 2.5  $\mu$ g Fz2 shRNA. Distance from the scratched line to the growing edge of the cells was measured in MKN45 (E) and MKN74 cells (F). Original magnification, x100; scale bar, 200  $\mu$ m; error bar, standard deviation; \*P<0.05; N=3.



Figure 6. Expression levels of matrix metalloproteinase 9. MKN45 (A) and MKN74 cells (B) were transfected with Fz2 shRNA and subjected to real-time quantitative polymerase chain reaction (PCR) for matrix metalloproteinase 9. Mock, mock transfected; neg, transfected with negative control;  $0.25 \mu g$ , transfected with 0.25  $\mu g$  shRNA; 2.5  $\mu g$  shRNA; error bar, standard deviation; \*P<0.05; N=3.

20.4 $\pm$ 3.6% (P<0.05) and 13.8 $\pm$ 2.8% (P<0.05) in MKN45 and MKN74 cells transfected with at 2.5  $\mu$ g Fz2 shRNA, respectively, as compared with mock transfections (Fig. 6A and B).

#### Discussion

Expression patterns of Fz genes in normal stomach have not been reported (22-29). In our study, Fz1, 2, 3, 6 and 8 were shown to be expressed in normal stomach. It has previously been demonstrated that the GC cell lines MKN45 and MKN74 are positive for Fz3 expression using northern blot analysis (23). In the present study, we also demonstrated that both cell lines were positive for Fz3 expression using RT-PCR. Our data showed that MKN45 and MKN74 cells were negative and positive for Fz4 and Fz6 expression, respectively, consistent with previous reports (24,26).

In contrast, the present data showed that Fz2 was upregulated in the MKN45 GC cell line, but downregulated in MKN74. Fz2 was chosen for further analysis to address the possibility that downregulation of Fz2 might suppress the

proliferation and motility of MKN45 and MKN74 cells. MTS and scratch assays clearly showed that Fz2 shRNA successfully suppressed the proliferation and motility of both cell lines. These results indicated that Fz2 might be a novel target for the development of molecular therapies for GC. We also observed Fz2-mediated downregulation of cyclin D1, which is involved in cell proliferation (20) and is also downregulated by an inhibitor of the Wnt pathway (17). These results and our data together suggested that Fz2 shRNA suppressed cell proliferation and motility via suppression of the Wnt pathway.

Our data clearly also demonstrated that *MMP9*, which has been established to be involved in cell motility (21), was downregulated by Fz2 shRNA in GC cell lines, which also demonstrated suppression of cell motility. As the expression of MMP9 is associated with the expression of Wnt3a in human primary lung cancer tissues (30), this, along with our results, suggested that MMP9 was a downstream target of the Wnt pathway.

One limitation of our study was that Fz2 was expressed in normal stomach. It was difficult to know what types of cells were positive for Fz1, 2, 3, 6 and 8. Stomach tissue is composed of mucous, muscle, and serous tissue, as well as nerves and blood vessels.

In conclusion, Fz2, 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 GC cell lines. Fz2 shRNA suppressed cell proliferation and motility of MKN45 and MKN74 cells, and cyclin D1 and *MMP9* expression was downregulated by Fz2 shRNA. Together, these results suggested that Fz2 might be a novel target for the development of molecular therapies for GC.

#### References

- 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
- Kim MY, Cho JH and Cho JY: Ever-changing endoscopic treatment for early gastric cancer: yesterday-today-tomorrow. World J Gastroenterol 20: 13273-13283, 2014.
- De Vita F, Di Martino N, Fabozzi A, *et al*: Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol 20: 14537-14558, 2014.
- Gomez-Orte E, Saenz-Narciso B, Moreno S and Cabello J: Multiple functions of the noncanonical Wnt pathway. Trends Genet 29: 545-553, 2013.
- Tanaka SS, Kojima Y, Yamaguchi YL, Nishinakamura R and Tam PP: Impact of WNT signaling on tissue lineage differentiation in the early mouse embryo. Dev Growth Differ 53: 843-856, 2011.
- MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26, 2009.
- 7. Takahashi-Yanaga F: Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 86: 191-199, 2013.
- 8. Jamieson C, Sharma M and Henderson BR: Targeting the betacatenin nuclear transport pathway in cancer. Semin Cancer Biol 27: 20-29, 2014.
- 9. Veeck J and Dahl E: Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta 1825: 18-28, 2012.
- Katoh M and Katoh M: WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13: 4042-4045, 2007.
- Qu Y, Dang S and Hou P: Gene methylation in gastric cancer. Clin Chim Acta 424: 53-65, 2013.
- Hibi K, Sakata M, Yokomizi K, *et al*: Methylation of the WNT5A gene is frequently detected in early gastric carcinoma. Hepatogastroenterology 59: 2661-2663, 2012.
- Hepatogastroenterology 59: 2661-2663, 2012.
  13. Katoh M: WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14: 1583-1588, 2005.
- 14. Cui J, Xi H, Cai A, Bian S, Wei B and Chen L: Decreased expression of Sox7 correlates with the upregulation of the Wnt/beta-catenin signaling pathway and the poor survival of gastric cancer patients. Int J Mol Med 34: 197-204, 2014.

- 15. Yu J, Tao Q, Cheng YY, *et al*: Promoter methylation of the Wnt/ beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 115: 49-60, 2009.
- Fujimoto T, Tomizawa M and Yokosuka O: SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells. Int J Oncol 35: 861-866, 2009.
- Tomizawa M, Shinozaki F, Motoyoshi Y, *et al*: Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway. Onco Targets Ther 6: 1685-1693, 2013.
- Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Frizzled-2: A potential novel target for molecular pancreatic cancer therapy. Oncol Lett 7: 74-78, 2014.
- Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S and Sueishi M: Short hairpin RNA of frizzled-2 suppresses the proliferation of hepatocellular carcinoma cells. Oncol Lett 8: 1519-1522, 2014.
- Casimiro MC, Velasco-Velazquez M, Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs 23: 295-304, 2014.
- Vandooren J, Van den Steen PE and Opdenakker G: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 48: 222-272, 2013.
- 22. Sagara N, Toda G, Hirai M, Terada M and Katoh M: Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Commun 252: 117-122, 1998.
- Kirikoshi H, Koike J, Sagara N, *et al*: Molecular cloning and genomic structure of human frizzled-3 at chromosome 8p21. Biochem Biophys Res Commun 271: 8-14, 2000.
- 24. Kirikoshi H, Sagara N, Koike J, *et al*: Molecular cloning and characterization of human Frizzled-4 on chromosome 11q14-q21. Biochem Biophys Res Commun 264: 955-961, 1999.
- Saitoh T, Hirai M and Katoh M: Molecular cloning and characterization of human Frizzled-5 gene on chromosome 2q33.3-q34 region. Int J Oncol 19: 105-110, 2001.
- 26. Tokuhara M, Hirai M, Atomi Y, Terada M and Katoh M: Molecular cloning of human Frizzled-6. Biochem Biophys Res Commun 243: 622-627, 1998.
- Saitoh T, Hirai M and Katoh M: Molecular cloning and characterization of human Frizzled-8 gene on chromosome 10p11.2. Int J Oncol 18: 991-996, 2001.
- 28. Wang YK, Samos CH, Peoples R, Perez-Jurado LA, Nusse R and Francke U: A novel human homologue of the *Drosophila* frizzled wnt receptor gene binds wingless protein and is in the Williams syndrome deletion at 7q11.23. Hum Mol Genet 6: 465-472, 1997.
- 29. Koike J, Takagi A, Miwa T, Hirai M, Terada M and Katoh M: Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family. Biochem Biophys Res Commun 262: 39-43, 1999.
- 30. Lee MA, Park JH, Rhyu SY, Oh ST, Kang WK and Kim HN: Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer 14: 125, 2014.